BMB Reports最新文献_第3页

ASCL1-mediated direct reprogramming: converting ventral midbrain astrocytes into dopaminergic neurons for Parkinson's disease therapy. ASCL1 介导的直接重编程：将腹侧中脑星形胶质细胞转化为治疗帕金森病的多巴胺能神经元。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-08-01

Sang Hui Yong, Sang-Mi Kim, Gyeong Woon Kong, Seung Hwan Ko, Eun-Hye Lee, Yohan Oh, Chang-Hwan Park

{"title":"ASCL1-mediated direct reprogramming: converting ventral midbrain astrocytes into dopaminergic neurons for Parkinson's disease therapy.","authors":"Sang Hui Yong, Sang-Mi Kim, Gyeong Woon Kong, Seung Hwan Ko, Eun-Hye Lee, Yohan Oh, Chang-Hwan Park","doi":"","DOIUrl":"","url":null,"abstract":"Parkinson's disease (PD), characterized by dopaminergic neuron degeneration in the substantia nigra, is caused by various genetic and environmental factors. Current treatment methods are medication and surgery; however, a primary therapy has not yet been proposed. In this study, we aimed to develop a new treatment for PD that induces direct reprogramming of dopaminergic neurons (iDAN). Achaete-scute family bHLH transcription factor 1 (ASCL1) is a primary factor that initiates and regulates central nervous system development and induces neurogenesis. In addition, it interacts with BRN2 and MYT1L, which are crucial transcription factors for the direct conversion of fibroblasts into neurons. Overexpression of ASCL1 along with the transcription factors NURR1 and LMX1A can directly reprogram iDANs. Using a retrovirus, GFP-tagged ASCL1 was overexpressed in astrocytes. One week of culture in iDAN convertsion medium reprogrammed the astrocytes into iDANs. After 7 days of differentiation, TH+/TUJ1+ cells emerged. After 2 weeks, the number of mature TH+/TUJ1+ dopaminergic neurons increased. Only ventral midbrain (VM) astrocytes exhibited these results, not cortical astrocytes. Thus, VM astrocytes can undergo direct iDAN reprogramming with ASCL1 alone, in the absence of transcription factors that stimulate dopaminergic neurons development. [BMB Reports 2024; 57(8): 363-368].","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140847983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and innovations in hematopoietic stem cell transplantation: exploring bone marrow niches and new model systems. 造血干细胞移植的挑战与创新：探索骨髓龛位和新模型系统。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-08-01

Byung-Chul Lee

{"title":"Challenges and innovations in hematopoietic stem cell transplantation: exploring bone marrow niches and new model systems.","authors":"Byung-Chul Lee","doi":"","DOIUrl":"","url":null,"abstract":"Hematopoietic stem cell transplantation (HSCT) remains an indispensable therapeutic strategy for various hematological diseases. This review discusses the pivotal role of bone marrow (BM) niches in influencing the efficacy of HSCT and evaluates the current animal models, emphasizing their limitations and the need for alternative models. Traditional animal models, mainly murine xenograft, have provided significant insights, but due to species-specific differences, are often constrained from accurately mimicking human physiological responses. These limitations highlight the importance of developing alternative models that can more realistically replicate human hematopoiesis. Emerging models that include BM organoids and BM-on-a-chip microfluidic systems promise enhanced understanding of HSCT dynamics. These models aim to provide more accurate simulations of the human BM microenvironment, potentially leading to improved preclinical assessments and therapeutic outcomes. This review highlights the complexities of the BM niche, discusses the limitations of current models, and suggests directions for future research using advanced model systems. [BMB Reports 2024; 57(8): 352-362].","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characterization of an orthotopic mouse transplant model reveals early changes in the tumor microenvironment of lung cancer. 正位小鼠移植模型的特征揭示了肺癌肿瘤微环境的早期变化。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-24

Minsu Na, Huiram Kang, Nayoung Kim, Areum Jo, Hae-Ock Lee

引用次数: 0

JMJD4 promotes tumor progression via inhibition of the PDCD5-TP53 pathway JMJD4 通过抑制 PDCD5-TP53 通路促进肿瘤进展

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-16 DOI: 10.5483/bmbrep.2024-0027

Hyunsik Kim, Subhin Jang, Soo Yeon Lee, Jae-Hwan Kwon, Seunghee Byun, Jung-Yoon Yoo, Sungryul Yu, Soo-Yeon Park, Ho-Geun Yoon

引用次数: 0

Neutrophils in MASLD and MASH MASLD 和 MASH 中的中性粒细胞

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-12 DOI: 10.5483/bmbrep.2024-0058

Sanjeeb Shrestha, Jae-Han Jeon, Chang-Won Hong

引用次数: 0

Potential role of ANGPTL4 in cancer progression, metastasis, and metabolism: a brief review ANGPTL4 在癌症进展、转移和新陈代谢中的潜在作用：简要回顾

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-09 DOI: 10.5483/bmbrep.2024-0082

Min Seok Park, Sang Eun Kim, Pureunchowon Lee, Ju-Hee Lee, Kyung Hee Jung, Soon-Sun Hong

引用次数: 0

Downregulated CDK10 promotes cancer progression and radioresistance in lung cancer through activating the JNK/c-Jun signaling pathway. 下调的 CDK10 通过激活 JNK/c-Jun 信号通路促进肺癌的癌症进展和放射抗性。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-01

Chaojin Hong, Yimei Meng, Anchen Qiu, Haibo Zhang, Liu Yang, Yupeng Hong, Yumei Huang

引用次数: 0

Prmt7 is required for the osteogenic differentiation of mesenchymal stem cells via modulation of BMP signaling. Prmt7是间充质干细胞通过调节BMP信号分化成骨所必需的。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-01

Tuan Anh Vuong, Yan Zhang, June Kim, Young-Eun Leem, Jong-Sun Kang

引用次数: 0

Identification and structure of AIMP2-DX2 for therapeutic perspectives. 鉴定 AIMP2-DX2 并确定其结构，展望治疗前景。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-01

Hyeon Jin Kim, Mi Suk Jeong, Se Bok Jang

{"title":"Identification and structure of AIMP2-DX2 for therapeutic perspectives.","authors":"Hyeon Jin Kim, Mi Suk Jeong, Se Bok Jang","doi":"","DOIUrl":"","url":null,"abstract":"Regulation of cell fate and lung cell differentiation is associated with Aminoacyl-tRNA synthetases (ARS)-interacting multifunctional protein 2 (AIMP2), which acts as a non-enzymatic component required for the multi-tRNA synthetase complex. In response to DNA damage, a component of AIMP2 separates from the multi-tRNA synthetase complex, binds to p53, and prevents its degradation by MDM2, inducing apoptosis. Additionally, AIMP2 reduces proliferation in TGF-β and Wnt pathways, while enhancing apoptotic signaling induced by tumor necrosis factor-β. Given the crucial role of these pathways in tumorigenesis, AIMP2 is expected to function as a broad-spectrum tumor suppressor. The full-length AIMP2 transcript consists of four exons, with a small section of the pre-mRNA undergoing alternative splicing to produce a variant (AIMP2-DX2) lacking the second exon. AIMP2-DX2 binds to FBP, TRAF2, and p53 similarly to AIMP2, but competes with AIMP2 for binding to these target proteins, thereby impairing its tumor-suppressive activity. AIMP2-DX2 is specifically expressed in a diverse range of cancer cells, including breast cancer, liver cancer, bone cancer, and stomach cancer. There is growing interest in AIMP2-DX2 as a promising biomarker for prognosis and diagnosis, with AIMP2-DX2 inhibition attracting significant interest as a potentially effective therapeutic approach for the treatment of lung, ovarian, prostate, and nasopharyngeal cancers. [BMB Reports 2024; 57(7): 318-323].","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma. VSTM2L 是胆管癌中一个很有前景的治疗靶点和预后可溶性生物标志物。

IF 2.9 3区生物学

BMB Reports Pub Date : 2024-07-01

Jungwhoi Lee, Woogwang Sim, Jungsul Lee, Jae-Hoon Kim

{"title":"VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma.","authors":"Jungwhoi Lee, Woogwang Sim, Jungsul Lee, Jae-Hoon Kim","doi":"","DOIUrl":"","url":null,"abstract":"The aim of the present study is to provide a rational background for silencing the V-set and transmembrane domain containing 2 like (VSTM2L) in consort with recognising soluble VSTM2L against cholangiocarcinoma. A therapeutic target against cholangiocarcinoma was selected using iterative patient partitioning (IPP) calculation, and it was verified by in vitro and in silico analyses. VSTM2L was selected as a potential therapeutic target against cholangiocarcinoma. Silencing the VSTM2L expression significantly attenuated the viability and survival of cholangiocarcinoma cells through blockade of the intracellular signalling pathway. In silico analysis showed that VSTM2L affected the positive regulation of cell growth in cholangiocarcinoma. Liptak's z value revealed that the expression of VSTM2L worsened the prognosis of cholangiocarcinoma patients. In addition, soluble VSTM2L was significantly detected in the whole blood of cholangiocarcinoma patients compared with that of healthy donors. Our report reveals that VSTM2L might be the potential therapeutic target and a soluble prognostic biomarker against cholangiocarcinoma. [BMB Reports 2024; 57(7): 324-329].","PeriodicalId":9010,"journal":{"name":"BMB Reports","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11289506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0